203 related articles for article (PubMed ID: 32571698)
1. One Year of Preemptive Valganciclovir Administration in Children After Liver Transplantation.
Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2020; 52(6):1852-1854. PubMed ID: 32571698
[TBL] [Abstract][Full Text] [Related]
2. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
Togashi J; Sugawara Y; Hashimoto M; Tamura S; Kaneko J; Aoki T; Hasegawa K; Kokudo N
Biosci Trends; 2011; 5(5):217-22. PubMed ID: 22101378
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant recipients: a single-center experience.
Iida T; Miura K; Ban H; Ando T; Shirai Y; Ishiwa S; Shiratori A; Kaneko N; Yabuuchi T; Ishizuka K; Takaiwa M; Suyama K; Hisano M; Hattori M
Clin Exp Nephrol; 2021 May; 25(5):531-536. PubMed ID: 33506359
[TBL] [Abstract][Full Text] [Related]
4. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
[TBL] [Abstract][Full Text] [Related]
5. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
8. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
Belga S; Hernandez C; Kabbani D; Cervera C
Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285
[TBL] [Abstract][Full Text] [Related]
9. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
12. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
[TBL] [Abstract][Full Text] [Related]
14. Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation.
Misaki Y; Kimura SI; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Yoshimura K; Gomyo A; Matsumi S; Akahoshi Y; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Nakasone H; Kako S; Kanda Y
Transpl Infect Dis; 2020 Jun; 22(3):e13270. PubMed ID: 32092224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
Singh N; Wannstedt C; Keyes L; Gayowski T; Wagener MM; Cacciarelli TV
Transplantation; 2005 Jan; 79(1):85-90. PubMed ID: 15714174
[TBL] [Abstract][Full Text] [Related]
16. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients.
Dupuis R; Harris M; Gillis K; Gerber D; Fair J; Watson R; Koslowski T; Andreoni K
Transplant Proc; 2007 Dec; 39(10):3266-70. PubMed ID: 18089368
[TBL] [Abstract][Full Text] [Related]
17. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S
Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
Fayek SA; Mantipisitkul W; Rasetto F; Munivenkatappa R; Barth RN; Philosophe B
HPB (Oxford); 2010 Dec; 12(10):657-63. PubMed ID: 21083790
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
Lopau K; Greser A; Wanner C
Clin Transplant; 2007; 21(1):80-5. PubMed ID: 17302595
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Ultralow-Dose Valganciclovir Chemoprophylaxis for Cytomegalovirus Infection in ABO-Incompatible Kidney Transplantation Recipients.
Lee JH; Hwang SD; Song JH; Kim JH; Kim HY; Lee DY; Oh JS; Sin YH; Kim JK
Transplant Proc; 2018 Oct; 50(8):2485-2488. PubMed ID: 30241930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
